Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
For patients too risky for redo heart surgery, placing a transcatheter aortic valve in the mitral position is proving to be a viable option. A UK study of 184 procedures found high technical success rates and significant symptom relief. However, outcomes varied considerably depending on the type of procedure performed.
For patients deemed too high-risk for repeat open-heart surgery, a minimally invasive alternative is showing real promise. A retrospective UK study covering 184 transcatheter mitral valve procedures across 12 centers (2016–2024) found that placing a transcatheter aortic valve off-label in the mitral position achieved high technical success and meaningful symptom improvement — with the proportion of patients in severe heart failure (NYHA class III–IV) dropping from 81% before the procedure to just 12% at last follow-up.
Not all procedures are created equal, though. Results varied significantly based on the anatomy involved, with valve-in-valve (MViV) procedures in failed surgical valves performing best, while valve-in-mitral annular calcification (ViMAC) cases — the most complex — carried substantially higher risk.
By the Numbers:
Why it matters: With many patients ineligible for conventional surgery, transcatheter mitral therapies fill a critical gap. These findings reinforce that patient selection and procedural complexity matter enormously — and that complex ViMAC cases should be referred to specialized, high-volume centers.
